Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection.

ABSTRACT: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivar

SUBMITTER: Tsai YF 

PROVIDER: S-EPMC8465128 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature